News
30 October
2020

The PB010 PureSelect2 project has been successfully completed!

We have succesfully completed the PB010 PureSelect2 project.

The aim was to develop an improved platform for the selection and production of antibody fragments
It allows the in vitro screening of antibody, which can then be produced in an appropriate cell system
The developed platform already supports our other internal research projects and services
Project value was 4’252’710 PLN, including 3’258’111 PLN from the European Regional Development Fund (76,6%)

PureSelect2 is the second technology platform in Pure Biologics, next to the PureApta for aptamer selection!

Article: 📰 Pure Biologics zakończył realizację projektu platformy selekcji przeciwciał PureSelect2 (🇵🇱)

Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.